July 3, 2024- The annual number of medtech acquisitions is on course to slump to its lowest level since 2017, according to Needham analysts. Deal volumes are down but values are up, and analysts see the potential for increased activity, citing stabilizing interest rates and low valuations. But they identified antitrust concerns as a barrier that could persist until at least the presidential election.